SG11202108140SA - Anti-bag2 antibody and methods of treating cancer - Google Patents
Anti-bag2 antibody and methods of treating cancerInfo
- Publication number
- SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA
- Authority
- SG
- Singapore
- Prior art keywords
- bag2
- antibody
- methods
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190016347A KR102172541B1 (ko) | 2019-02-12 | 2019-02-12 | Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법 |
| KR1020190016359A KR102241558B1 (ko) | 2019-02-12 | 2019-02-12 | Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 |
| PCT/IB2020/051136 WO2020165794A1 (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108140SA true SG11202108140SA (en) | 2021-08-30 |
Family
ID=72044199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108140SA SG11202108140SA (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230183324A1 (de) |
| EP (2) | EP3938788A4 (de) |
| JP (2) | JP2022521706A (de) |
| CN (2) | CN114761803A (de) |
| AU (1) | AU2020222326A1 (de) |
| BR (1) | BR112021015940A2 (de) |
| CA (1) | CA3129748A1 (de) |
| MX (1) | MX2021009690A (de) |
| SG (1) | SG11202108140SA (de) |
| WO (2) | WO2020165797A1 (de) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
| WO2008123867A1 (en) * | 2007-04-05 | 2008-10-16 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of breast cancer |
| EP2250282A4 (de) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten |
| US20100204055A1 (en) * | 2008-12-05 | 2010-08-12 | Bonner-Ferraby Phoebe W | Autoantibody detection systems and methods |
| KR102039624B1 (ko) * | 2017-03-03 | 2019-11-01 | 재단법인 차세대융합기술연구원 | BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법 |
| KR102230314B1 (ko) * | 2017-10-24 | 2021-03-22 | 주식회사 메드팩토 | 혈액으로부터 암을 진단하는 방법 |
-
2020
- 2020-02-12 MX MX2021009690A patent/MX2021009690A/es unknown
- 2020-02-12 BR BR112021015940-1A patent/BR112021015940A2/pt unknown
- 2020-02-12 CA CA3129748A patent/CA3129748A1/en active Pending
- 2020-02-12 JP JP2021547311A patent/JP2022521706A/ja active Pending
- 2020-02-12 EP EP20755277.9A patent/EP3938788A4/de active Pending
- 2020-02-12 CN CN202080028383.7A patent/CN114761803A/zh active Pending
- 2020-02-12 EP EP20755764.6A patent/EP3924382A4/de active Pending
- 2020-02-12 WO PCT/IB2020/051139 patent/WO2020165797A1/en unknown
- 2020-02-12 CN CN202080027907.0A patent/CN114269779A/zh active Pending
- 2020-02-12 WO PCT/IB2020/051136 patent/WO2020165794A1/en unknown
- 2020-02-12 AU AU2020222326A patent/AU2020222326A1/en active Pending
- 2020-02-12 US US16/758,930 patent/US20230183324A1/en active Pending
- 2020-02-12 SG SG11202108140SA patent/SG11202108140SA/en unknown
- 2020-02-12 US US16/758,934 patent/US20230194534A1/en active Pending
- 2020-02-12 JP JP2021547308A patent/JP2022525843A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021015940A2 (pt) | 2021-10-05 |
| CA3129748A1 (en) | 2020-08-20 |
| WO2020165794A1 (en) | 2020-08-20 |
| AU2020222326A1 (en) | 2021-08-19 |
| EP3924382A4 (de) | 2023-01-04 |
| MX2021009690A (es) | 2021-10-01 |
| EP3938788A4 (de) | 2023-01-04 |
| WO2020165797A1 (en) | 2020-08-20 |
| CN114269779A (zh) | 2022-04-01 |
| JP2022525843A (ja) | 2022-05-20 |
| EP3938788A1 (de) | 2022-01-19 |
| EP3924382A1 (de) | 2021-12-22 |
| CN114761803A (zh) | 2022-07-15 |
| US20230194534A1 (en) | 2023-06-22 |
| JP2022521706A (ja) | 2022-04-12 |
| US20230183324A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289663A (en) | Claudin 18 antibodies and methods for cancer treatment | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| ZA202004735B (en) | Anti-pd-1 antibodies and methods of treatment | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| IL266990A (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| IL281441B (en) | Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer | |
| IL288086A (en) | Methods and materials for cancer treatment | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL282478A (en) | Materials and methods for cancer treatment | |
| SG11202111672RA (en) | Cancer associated antibody compositions and methods of use | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| SG11202107017TA (en) | Methods of treating cancer | |
| IL285352A (en) | Anti-nme antibody and method for treating cancer or cancer metastases | |
| IL289811A (en) | A method for treating cancer | |
| EP3759125A4 (de) | Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| IL281600A (en) | Methods of treating cancer | |
| IL277981A (en) | Cancer treatment methods | |
| IL287687A (en) | Methods of treating cancer with an anti-pd-l1 antibody | |
| ZA202105583B (en) | Methods of diagnosing and treating cervical cancer | |
| EP4061421A4 (de) | Behandlung von krebs mit anti-ox40-antikörpern und multi-kinase-inhibitoren | |
| SG11202108140SA (en) | Anti-bag2 antibody and methods of treating cancer | |
| EP3585819A4 (de) | Antikörperkonstrukte und verfahren zur behandlung von krebs | |
| IL307556A (en) | Cancer treatment methods using antibodies against TIGIT | |
| IL283912B (en) | Methods for treating cancer using the platenoside molecule and its isomers |